Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

41. Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Article

2017 Evidence-Based Medicine

42. The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial (Abstract)

The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial Tranexamic acid (TXA) was reportedly to decrease postoperative blood loss after standard total knee arthroplasty (TKA). However, the blood-conservation effect of TXA in minimally invasive TKA, in particular, receiving a direct oral anticoagulant was unclear. The aim of the study was to investigate the efficacy of combined (...) use of TXA and rivaroxaban on postoperative blood loss in primary minimally invasive TKA.In a prospective, randomized, controlled trial, 198 patients were assigned to placebo (98 patients, normal saline injection) and study group (100 patients, 1g TXA intraoperative injection) during primary unilateral minimally invasive TKA. All patients received rivaroxaban 10 mg each day for 14 doses postoperatively. Total blood loss was calculated from the maximum hemoglobin drop after surgery plus amount

2016 EvidenceUpdates

43. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Full Text available with Trip Pro

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxaban in the United States.A retrospective (...) cohort study was conducted to compare the major bleeding risk among newly anticoagulated NVAF patients initiating warfarin, apixaban, dabigatran or rivaroxaban. The study used the Truven MarketScan(®) Commercial & Medicare supplemental US database from 1 January 2013 through 31 December 2013. Major bleeding was defined as bleeding requiring hospitalisation. Cox model estimated hazard ratios (HRs) of major bleeding were adjusted for age, gender, baseline comorbidities and co-medications. Among 29 338

2016 EvidenceUpdates

44. Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? Full Text available with Trip Pro

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold-standard treatment, but the costs involved limit its use, especially in developing countries. Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE (...) treatment.We conducted a retrospective analysis from January 2009 to February 2014 with patients who had cancer and VTE who were receiving rivaroxaban. We compared the efficacy, safety, and cost of rivaroxaban and low molecular weight heparin (LMWH) alone or followed by vitamin K antagonists.Forty-one patients were identified, with a median age of 62.5 years. The most frequent tumor histology was adenocarcinoma (78%), which was most often found in the colon (26.8%). Most participants had advanced disease

2016 Journal of global oncology

45. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding Full Text available with Trip Pro

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding Outpatient treatment of acute venous thromboembolism (VTE) requires the selection of patients with a low risk of bleeding during the first few weeks of anticoagulation. The accuracy of four systems, originally derived for predicting bleeding in VTE treated with vitamin K antagonists (VKAs), was assessed in VTE patients treated with rivaroxaban.All patients (...) treated with rivaroxaban in the multinational EINSTEIN deep vein thrombosis (DVT) and pulmonary embolism (PE) trials were included. Major bleeding was defined as ≥2 g/dL drop in hemoglobin or ≥2-unit blood transfusion, bleeding in critical area, or bleeding contributing to death. The authors examined the incidence of major bleeding in patients with low-risk assignment by the systems of Ruiz-Gimenez et al. (score = 0 to 1), Beyth et al. (score = 0), Kuijer et al. (score = 0), and Landefeld and Goldman

2016 EvidenceUpdates

46. Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Full Text available with Trip Pro

Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Direct oral anticoagulants (DOACs or NOACs -non-vitamin K oral anticoagulants), as the name suggests, are oral anticoagulants with a direct inhibitory action either against factor X or factor II (thrombin). Pregnant women were excluded from participating in all the large trials of the DOACs and they are considered contra-indicated in pregnancy and breast feeding. We present a case of inadvertent exposure to rivaroxaban

2015 Obstetric medicine

47. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

2015 BestBETS

48. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation Full Text available with Trip Pro

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA).Trial size was administratively set at 250, the protocol-specified target. Events were independently and blindly adjudicated. We randomly assigned 248 NVAF patients (...) to uninterrupted rivaroxaban (20 mg once-daily) or to an uninterrupted VKA prior to CA and for 4 weeks afterwards. The primary endpoint was major bleeding events after CA. Secondary endpoints included thromboembolic events (composite of stroke, systemic embolism, myocardial infarction, and vascular death) and other bleeding or procedure-attributable events. Patients were 59.5 ± 10 years of age, 71% male, 74% paroxysmal AF, and had a CHA2DS2-VASc score of 1.6. The average total heparin dose used to manage

2015 EvidenceUpdates Controlled trial quality: predicted high

49. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study Full Text available with Trip Pro

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients.A post hoc (...) analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified PESI scores. Recurrent venous thromboembolism, fatal PE, all-cause mortality, and major bleeding were stratified by simplified PESI scores of 0, 1, or ≥2 and according to treatment period at 7, 14, 30, and 90 days and at the end of the full intended treatment period.Simplified PESI scores could be calculated in 4,831 of the 4,832 randomized patients; of those, 53.6, 36.7

2015 EvidenceUpdates Controlled trial quality: uncertain

50. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in (Abstract)

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct

2015 Lancet

51. Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto) © 2015 Thrombosis Canada Page 1 of 3 RIVAROXABAN (XARELTO ? ) OBJECTIVE: To provide an overview of the mechanism of action, licensed indications, dosing regimens and side- effects for rivaroxaban. BACKGROUND: Rivaroxaban (Xarelto ? ) is an oral factor Xa inhibitor. By binding reversibly to the active site of factor Xa, rivaroxaban attenuates thrombin generation and reduces fibrin formation. INDICATIONS: Rivaroxaban is currently licensed in Canada for: ? Thromboprophylaxis (...) thereafter. ? Rivaroxaban should not be used in patients with a CrCl 50 mL/min or 15 mg OD for those with CrCl 30-49 mL/min. MONITORING: Routine laboratory monitoring is unnecessary. Although the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) do not provide reliable measures of rivaroxaban’s anticoagulant activity, the prothrombin time is more responsive. Anti- factor Xa assays using rivaroxaban calibrators, where available, can be used

2015 Thrombosis Interest Group of Canada

52. In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age Full Text available with Trip Pro

In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age 25402538 2015 04 14 2018 12 02 1539-3704 161 10 2014 Nov 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. JC5 10.7326/0003-4819-161-10-201411180-02005 Rondina Matthew M eng K23 HL092161 HL NHLBI NIH HHS United States R01 AG048022 AG NIA NIH HHS United

2014 Annals of Internal Medicine

53. Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome

Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome Prescrire IN ENGLISH - Spotlight ''Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome'', 1 October 2014 {1} {1} {1} | | > > > Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome FEATURED REVIEW It has not been demonstrated that adding rivaroxaban to aspirin alone or to aspirin plus clopidogrel benefits patients who have had an acute coronary syndrome. The risk of serious and fatal bleeds is probably underestimated. Caution dictates that rivaroxaban should

2014 Prescrire

54. Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety

Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Apixaban and rivaroxaban for stroke (...) prevention in atrial fibrillation: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Reference List. 2014 Authors' conclusions Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non-randomized studies were identified regarding adverse events associated with the use of apixaban and rivaroxaban. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Atrial Fibrillation; Humans; Morpholines

2014 Health Technology Assessment (HTA) Database.

55. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism

Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism (...) . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months. If treatment is to be extended beyond six months, the following condition must be met. Condition: A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Final publication

2014 Health Technology Assessment (HTA) Database.

56. Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience

Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Prescrire IN ENGLISH - Spotlight ''Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience '', 1 June 2013 {1} {1} {1} | | > > > Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience FEATURED REVIEW Dabigatran, rivaroxaban and apixaban are oral anticoagulants used to prevent or treat thrombosis. Difficulties in the management of bleeding weigh heavily in the balance of potential harm versus potential benefit of these drugs. Full review (5 pages) available for download by subscribers. Abstract Dabigatran, rivaroxaban and apixaban

2014 Prescrire

57. Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation Title: Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation: Safety DATE: 28 March 2014 RESEARCH QUESTIONS 1. What are the adverse events associated with the use of apixaban? 2. What are the adverse events associated with the use of rivaroxaban? KEY MESSAGE Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non- randomized studies were identified regarding adverse events (...) associated with the use of apixaban and rivaroxaban. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to safety data. Where possible, retrieval was limited to the human population. The search was also limited

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

58. Rivaroxaban - Thromboembolic events (venous), pulmonary embolism

Rivaroxaban - Thromboembolic events (venous), pulmonary embolism Common Drug Review CDEC Meetings: October 16, 2013; January 15, 2013; March 19, 2014 Notice of Final Recommendation — March 26, 2014 Page 1 of 6 © 2014 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto — Bayer Inc.) New Indication: Pulmonary Embolism Recommendation: CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months (...) . If treatment is to be extended beyond six months, the following condition must be met: Condition: ? A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Reason for the Recommendation: 1. In one randomized controlled trial (RCT) involving patients with acute PE (EINSTEIN-PE), rivaroxaban was reported to be non-inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT, non-fatal PE, or fatal PE. Given

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

59. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) . Interventions The four interventions were warfarin, apixaban 5mg twice daily, dabigatran 150mg twice daily, and rivaroxaban 20mg once daily. Warfarin dose was assumed to be adjusted to achieve the patient's target international normalised ratio (INR). Location/setting USA/in-patient and out-patient care. Methods Analytical approach: A Markov model, with one-month cycles, combined the published data. The time horizon was 30 years and the authors stated that the perspective was societal. Effectiveness data

2013 NHS Economic Evaluation Database.

60. Rivaroxaban - stroke prevention in patients with atrial fibrillation

Rivaroxaban - stroke prevention in patients with atrial fibrillation Common Drug Review CDEC Meeting – June 19, 2013 Notice of CDEC Final Recommendation – July 18, 2013 Page 1 of 6 © 2013 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the prevention of stroke and systemic embolism in patients with atrial fibrillation who (...) meet all of the following clinical criteria: Clinical Criteria: 1. Patients with a CHADS 2 score = 2. 2. Patients who are unable to readily achieve adequate anticoagulation with warfarin. Reasons for the Recommendation: 1. In one large, double-blind, randomized controlled trial (RCT) of patients with a CHADS 2 score of greater than or equal to 2 (ROCKET-AF), rivaroxaban was reported to be non- inferior, but not superior, to adjusted-dose warfarin, based on the incidence of stroke or systemic

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review